Scientists hunt for clues to stop rare, deadly scleroderma
NCT ID NCT07345052
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study aims to uncover why systemic sclerosis (SSc) develops and worsens. Researchers will analyze blood, skin, and DNA from 150 patients in Sweden to find markers linked to disease activity and progression. The goal is to improve diagnosis and identify new treatment targets, but no direct therapy is being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify new markers to predict disease progression and potential drug targets for systemic sclerosis.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and findings may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROSIS LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rheumatology clinics, Sahlgrenska University Hospital
RECRUITINGGothenburg, Sweden, 41346, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire spot how rheumatic lung disease affects daily life?
- Are women with autoimmune diseases getting the gynecological care they need?
- New shot aims to tame rare autoimmune disease
- Cancer drug shows promise for rare skin disease
- New device AVELI tackles cellulite and fibrosis in liposuction patients
- Scientists probe immune Cells' role in scleroderma blood vessel injury